

NEWS RELEASE

Contact: Mark S. DiSalvo
978 794-3366 X 322
mdisalvo@sema4usa.com

SEMAPHORE REPRESENTS EXCLUSIVE LICENSE FROM BETH ISRAEL DEACONESS MEDICAL CENTER TO DEVELOP NEW ANEMIA DRUG

DNAPrint genomics obtains license from Harvard affiliate.

Boston, MA, April 14, 2005 –Semaphore announced today that it successfully represented the acquisition of an exclusive worldwide license from **Harvard Medical School’s Beth Israel Deaconess Medical Center (BIDMC)** to **DNAPrint genomics, Inc. (OTC BB: DNAP)** with intent to develop a new, more potent and longer acting form of the anemia drug Erythropoietin (EPO).

“We are pleased to have enjoyed the confidence of a premier medical research institution in Beth Israel to represent this critical technology and are pleased to work with a dynamic forward thinking biotech and pharmaceutical organization such as DNAPrint,” said Mark S. DiSalvo, CEO of Semaphore.

“Our EPO technology has significant promise as a more powerful and commercially successful application of Erythropoietin,” stated BIDMC’s Dr. Arthur J. Sytkowski, who holds patents related to the new “Super”-EPO. “We are pleased that DNAPrint has made a commitment to work with BIDMC in expanding the potential for this drug.”

“This licensing agreement is part of an overarching strategy to utilize recent genomics and chemistry advances made by researchers at DNAPrint to develop next-generation drugs that maximize efficacy and minimize side effects by tailoring medication for specific individuals and well-defined population sectors, “ said DNAP CEO Richard Gabriel.

The royalty bearing licensing agreement creates an opportunity for DNAPrint genomics to develop and market an improved “Super”- EPO. EPO is currently commercialized by several pharmaceutical companies for a worldwide market that exceeds \$10 billion, and the EPO market is growing at an average annual rate of 21%. Leading participants in the existing monomer EPO market include Amgen, Johnson & Johnson, and Roche.

EPO is a glycoprotein naturally made by the body to stimulate red blood cell production; the marketed forms are manufactured by recombinant DNA technology and are used to treat anemia or low blood cell count that results from a variety of illnesses and conditions. PT-401, the improved version of EPO licensed by DNAPrint is an Erythropoietin dimer, or a double form of the natural protein.

DNAP stated that it intends to devote a very significant proportion of its resources to fund and execute the PT-401 development program. EPO exhibits an element of variable response that DNAPrint management believes existing company technology can help address. “PT-401 will be coupled with a genetic test for predicting response and individualizing dosage, thereby providing personalized treatment,” said Hector J. Gomez, MD, Ph.D., DNAPrint’s Chairman and Chief Medical Officer. “We believe we have made a wise choice in selecting PT-401 to apply our genomics expertise -- expertise

which is not restricted to xenobiotic metabolism genetics but inclusive of far more complex gene-drug interactions. We appreciated working with Semaphore in its professional representation of this important BIDMC science,” he added.

The human gene that produces EPO was cloned in 1985 and in 1989, scientists at Amgen introduced to market a recombinant form under the trade name EPOGEN[®], a drug that many credit for the rise of Amgen in the 1990s as one of the world’s most successful biotechnology companies ever.

Patients undergoing certain therapies or with certain conditions are often rendered anemic, meaning their red blood cell count drops dramatically. Without adequate amounts of erythropoietin in the blood, red blood cells are not regenerated efficiently, and there are too few red blood cells to deliver oxygen sufficiently throughout the body. Erythropoietin has been approved by the U.S. Food and Drug Administration as a treatment for anemia associated with renal failure, cancer chemotherapy, zidovudine-treated HIV-infected patients and to reduce blood transfusion in surgery patients. Anemia leaves patients tired, often impairing their ability to work or perform even routine tasks and over the last decade, EPO has proven to improve quality of life and overall fitness of those patients.

In 1995, Dr. Sytkowski, Director for the Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology at Beth Israel Deaconess, was awarded the first in a string of eight patents covering methods of producing and using recombinant protein multimers with increased biological activity. In these patents, which are subject of the exclusive DNAPrint license announced today, Dr. Sytkowski described a new dimer (double) form of EPO -- “Super”-EPO, that elicited a heartier, more predictable hematocrit (red blood cell count) response, constituting a significant improvement over existing EPO technology.

Semaphore was engaged by BIDMC to seek licensing partners for this technology in 2004.

About Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.harvard.edu.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company’s ANCESTRYby DNA[™] is a consumer product for individuals interested in learning their family heritage. DNAWitness[™] is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME[™], a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME[™], a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction.. For more information about the company, please visit www.dnaprint.com.

About Semaphore

Semaphore is a seventeen-year old consultancy headquartered in Boston, with offices in London, New York City and Zurich, focused on providing Private Equity, Technology

and Business Advisory Services. With roots in consulting and operations it provides an extensive array of services including: interim fund management, technology diligence, portfolio company operations assistance, project assurance, technology transfer, investment audit, and market/channel development.

Semaphore business services span areas from emerging technologies to enterprise software to life sciences. Over the years these services have been provided to a broad spectrum of venture capital, legal, corporate, government and medical and academic research institutions around the globe. Semaphore's real-world practitioner reputation for discovering, defining and solving critical corporate and institutional needs is known worldwide. www.sema4usa.com